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Summary In the aim to evaluate the relationship between sputum eosinophil
percentages and eosinophil cationic protein (ECP) concentrations, as markers of
airway inflammation, and different levels of asthma severity, we examined 223
patients consecutively observed in our asthma clinic. Diagnosis of asthma was made
according to internationally accepted criteria. Asthma severity was evaluated
according to frequency of symptoms, FEV1, peak expiratory flow variability and level
of asthma treatment needed to control asthma. Spontaneous or induced sputum was
collected. Adequate sputum samples were obtained in 68 untreated subjects and in
117 subjects regularly treated with ICS. A control group of 14 normal subjects was
also examined.
In untreated subjects, mild intermittent asthmatics showed a lower sputum
eosinophil percentage in comparison with other groups of asthma severity, while no
difference in ECP levels was detected. In treated subjects, severe asthmatics
showed higher levels of sputum eosinophils and ECP in comparison with other groups
of asthma severity. Mild persistent and moderate persistent patients did not differ
for sputum eosinophils or ECP in both untreated and treated subjects. Controls were
significantly different from all groups of untreated and treated asthmatics.
In conclusion, the assessment of asthma severity according to clinical and
functional findings only partially corresponds to the severity of eosinophilic airway
inflammation as assessed by induced sputum analysis.
& 2003 Elsevier Ltd. All rights reserved.
Introduction
It is well established that one of the main features of
asthma is the presence of airway inflammation, with
involvement of several cellular populations and the
release of many inflammatory mediators.1 Eosinophils
in particular, with the release of cytotoxic proteins
such as eosinophil cationic protein (ECP), are
considered a good marker of airway inflammation in
asthma. The recovery of airway lining fluid can be a
valid tool to evaluate the degree of airway inflam-
mation, and in the last few years induced sputum has
been increasingly adopted at this purpose, as a non-
invasive, safe2 and reproducible method.3,4
The definition of the severity of asthma is crucial
to decide the level of antiasthma treatment.
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Current international guidelines recommend to
evaluate the level of asthma severity according to
the frequency and severity of symptoms and asthma
exacerbations, use of rescue medication and level of
pulmonary function.5 However, it is not completely
defined how much clinical and functional findings
correspond to biological markers of airway inflam-
mation. In general, the correlation between func-
tional and biological markers of asthma severity is
believed to be poor.6,7 In particular, Rosi et al.7
applied factor analysis to the study of 99 stable
asthmatics; they showed that airway function,
degree of bronchial hyper-responsiveness and eosi-
nophilic airway inflammation loaded on different
factors, suggesting that these factors can be
considered as separate dimensions in the description
of chronic asthma. Other studies found a mild but
significant relationship between airway inflamma-
tory markers and asthma severity.8–11 However,
limits of these papers are represented by a non-
standardized assessment of asthma severity,9 a low
number of examined subjects or by the lack of
stratification by asthma treatment, particularly with
inhaled corticosteroids which can affect the severity
of eosinophilic airway inflammation.8,10,11
In this study we evaluated if sputum markers of
eosinophilic airway inflammation (as eosinophil
percentage and ECP concentration) could discrimi-
nate between different degree of asthma severity
as assessed according to internationally accepted
criteria, in a large group of asthmatic patients with
or without regular pharmacological treatment. In
particular, we wanted to assess whether the clinical
distinction in four levels of asthma severity of the
International Guidelines5 was reflected by a similar
difference in sputum markers of eosinophilic airway
inflammation both in subjects not regularly treated
and in subjects under regular treatment with
inhaled corticosteroids.
Subjects and methods
Subjects
We examined 223 patients observed consecutively
in our asthma clinic during a 15-month period (from
January 1, 1997 to March 31, 1998). At the first
observation in our clinic, diagnosis of asthma was
made according to internationally accepted criter-
ia5 after assessing the presence of typical asthma
symptoms, reversible airway obstruction (increase
in FEV1 greater than 15% after inhalation of 200mcg
of salbutamol) and/or bronchial hyper-responsive-
ness to methacholine (PD20FEV1o1mg). All sub-
jects were examined at least 4 weeks from an acute
asthma exacerbation.
Eighty-six subjects were either steroid-naive, or
had been previously treated with inhaled corticos-
teroids but not in the last 3 months before
observation (Group A). One hundred and thirty-
seven subjects were observed when they were still
under regular treatment with inhaled corticoster-
oids, associated or not with regular bronchodilators
and/or oral corticosteroids (Group B).
We also examined 14 normal subjects (10 males
and four females), with a mean age of 3476 years.
All subjects were non-smokers, referred no history
of asthma or other respiratory diseases, and their
FEV1 was normal.
Clinical evaluation
All subjects underwent a detailed clinical history, in
order to evaluate the frequency of diurnal and
nocturnal symptoms (particularly in the last 3
months), use of rescue medication, duration of
asthma, smoking habit and other relevant diseases.
Pulmonary function tests were performed by a
computerized water sealed bell spirometer (Bio-
medin, Padua, Italy), and predicted values were
derived from Paoletti et al.12
Allergologic evaluation consisted in skin prick
test with a group of 11 common allergens (mites,
pollens, danders and moulds). Atopy was evaluated
as a positive response (wheal diameter X3mm) to
one at least of the allergens.
Methacholine challenge test was performed in
subjects without regular treatment, and in subjects
with regular treatment after withdrawal of bronch-
odilators for 48 h. Methacholine (Sigma, St. Louis,
MO, USA) was delivered by a Devilbiss 646 jet
nebulizer using the procedure described elsewhere
using a dosimetric technique.13 PD20FEV1 (the
cumulative dose producing 20% fall in FEV1 in
comparison with the post-diluent value) was
computed. A PD20FEV1 value lower than 1mg of
methacholine was considered as positive for non-
specific bronchial hyper-responsiveness.
Peak flow variability was assessed by a 2 week
monitoring of peak expiratory flow (PEF) by Mini-
Wright Peak Flow Meter (morning and evening
measurements). A maximal amplitude over mean
greater than 20% in 2 or more days a week was
considered as abnormal variability.
Assessment of asthma severity
At the time of sputum collection, all subjects were
carefully investigated on the frequency of diurnal
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and nocturnal symptoms in the last month, the
number of asthma exacerbations in the last 3–6
months, the use of rescue inhaled b2-agonists in the
last month, and the level of antiasthma treatment
currently performed. In almost all untreated sub-
jects and in part of treated subjects, PEF monitor-
ing was also obtained.
In subjects without regular treatment at the time
of the examination, asthma severity was assessed
according to GINA criteria, considering the fre-
quency of diurnal and nocturnal symptoms and the
frequency of rescue medication over the month
preceding sputum collection, the number and
severity of acute asthma exacerbations in the last
3 months, and FEV1 values measured immediately
before sputum induction.5 The level of asthma
severity was defined when one or more of the
following criteria were satisfied: (a) mild inter-
mittent asthma: symptoms less then once a week,
brief exacerbations, nocturnal symptoms not more
than once a month, occasional use of rescue
medication, no PEF variability and FEV1480%
pred.; (b) mild persistent asthma: symptoms and
use of rescue medication more than once a week,
but less than once a day, exacerbations affecting
activity and sleep, nocturnal symptoms more than
twice a month, mild PEF variability (maximal
amplitude 420% in more than 2 but not in all days
in a week), and FEV1 480% pred.; (c) moderate
persistent asthma: daily symptoms, exacerbations
affecting activity and sleep, nocturnal symptoms
more than once a week, daily use of rescue
medication, high PEF variability (maximal ampli-
tide420% in almost all days), and FEV1 60–80%
pred.; (d) severe persistent asthma: daily symp-
toms, frequent exacerbations and nocturnal asth-
ma symptoms, limitation of physical activities, high
PEF variability, and/or FEV1o60% pred.
In subjects under regular treatment with inhaled
corticosteroids, asthma severity was evaluated
according to the previous criteria, associated with
the level of antiasthma treatment needed to
control the disease.5 All subjects have been treated
for at least 6 months with the minimum level of
pharmacologic antiasthma treatment able to con-
trol symptoms. In particular, the level of asthma
severity was defined as follows: (a) mild persistent
asthma: regular treatment with low dose inhaled
corticosteroids (p400–500 mg daily), occasional
symptoms and rescue medication, no exacerba-
tions, and FEV1480% pred.; (b) moderate persis-
tent asthma: inhaled corticosteroids 500–1000 mg
daily, associated with long-acting bronchodilators
or leukotriene modifiers (in three patients), occa-
sional symptoms and rescue medication, no ex-
acerbations, and FEV1480% pred.; (c) severe
persistent asthma: high dose inhaled corticoster-
oids (41000 mg daily), associated with long-acting
bronchodilators, leukotriene modifiers, and oral
corticosteroids (in four patients), with or without
good control of asthma symptoms and pulmonary
function; therefore, according to the presence or
not of a good asthma control, severe asthmatics
were subdivided in stable (n ¼ 19) and unstable
(n ¼ 13) subjects. In mild persistent and moderate
asthmatic subjects, PEF variability, when available,
confirmed the obtained control of asthma.
Sputum collection and processing
Sputum samples were collected either sponta-
neously (n ¼ 76) or after induction by hypertonic
saline inhalation (n ¼ 147).
Sputum induction and processing was performed
according to the method previously described.14
Inhaled b2-agonist was administered as a pretreat-
ment, 10min before hypertonic saline inhalation,
only in subjects with FEV1p70% of predicted
(n ¼ 44). Hypertonic saline solution was nebulized
with an ultrasonic nebulizer (Sirius, Technomed,
Florence, Italy) with a 2.8ml/min output, and was
inhaled for 5min periods for up to 30min. NaCl
concentration was increased at intervals of 10min
from 3% to 4% to 5%. Every 5min from the start of
nebulization, subjects were asked to rinse their
mouth and throat carefully to discard saliva and to
try to cough sputum into a container; FEV1 was then
measured. Nebulization was stopped either after
30min or when FEV1 fell by 20% or more from
baseline.
Sputum was processed by the whole sample
method. Sputum samples were diluted with an
equal volume of 0.1% dithiotreithol (Sputasol;
Unipath Ltd., Basingstoke, UK) in phosphate buf-
fered saline. Samples were incubated in a shaking
bath at 371C for 15min and aspirated in and out of a
pipette to dissolve mucus plugs. The material was
filtered through a 53 mm nylon gauze (Giuliani
Filtrazioni, Torino, Italy). Aliquots (50–100 ml) of
sputum sample were cytocentrifuged (Cytospin;
Shandon Scientific, Sewickley, PA) and stained with
Diff-Quik (Baxter Scientific Products, Miami, FL) for
differential cell count. Two investigators, blinded
to the subject’s code, each first counted at least
500 cells on each sputum slide so as to obtain the
squamous cell percentage as an indicator of
salivary contamination. At least 300 non-squamous
cells were counted. Macrophage, lymphocyte,
neutrophil, eosinophil percentages were thus ex-
pressed as percent of total inflammatory cells,
excluding squamous cells. The remainder of the
ARTICLE IN PRESS
186 M.L. Bartoli et al.
sputum sample was centrifuged at 400g for 10min.
The cell pellet was resuspended in normal saline for
total cell counts with the T .urk staining and cell
viability assessment by Trypan blue exclusion test.
The quality of each slide was assessed. Adequate
samples were those with viability greater than 70%,
at least 300 inflammatory cells counted, with good
or fair integrity of cells and cell distribution.
Interobserver reproducibility for differential cell
counts was assessed on 25 slides randomly selected,
and it was reported as good.4
ECP measurement
ECP in sputum supernatant was measured in part of
the samples by means of specific and sensitive
radioimmunoassays (Pharmacia RIA, Uppsala, Swe-
den), with a detection limito2 ng/ml.
Statistical analysis
Clinical and functional data are reported as
mean7SD. Inflammatory cells in the sputum are
reported as absolute counts (cells/ml of sputum)
and as percentages of total cell counts (median and
range). Sputum ECP concentrations are reported as
median and range. PD20FEV1 methacholine was log
transformed for statistical evaluation and ex-
pressed as geometric mean.
ANOVA and non-parametric Kruskall–Wallis or
Mann–Witney tests were used to compare different
groups of subjects for normally or non-normally
distributed data. Groups including less than three
subjects were excluded from the analysis. Analysis
of correlation was achieved using Spearman’s rank
correlation coefficient. A P value lower than 0.05
was considered as statistically significant.
Results
Thirty-eight out of 223 subjects produced an
inadequate sputum sample, and thus were ex-
cluded from the analysis. Clinical and functional
data of the remaining 185 subjects are reported in
Table 1. No significant difference among groups of
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Table 1 Main clinical and functional characteristics of subjects.
Mild intermittent Mild persistent Moderate Severe
Untreated subjects
N 15 21 31 (1)
Age, yr (m7SD) 33716 37718 38715 47
Sex, m; n (%) 7 (47%) 9 (49%) 14 (45%) 1
Smoking habit
Yes 3 (20%) 3 (12%) 7 (25%)
Ex 4 (27%) 6 (29%) 6 (19%)
No 8 (53%) 12 (59%) 18 (56%) 1
Atopy, yes, n (%) 8 (57%) 11 (55%) 21 (67%) 0
FEV1 (% pred) 97.0711.3 93.6711 81.8716
n 48
PD20FEV1 (g. mean) 0.823
w (n ¼ 9) 0.229 (n ¼ 11) 0.149 (n ¼ 15) F
Treated subjects
N 34 51 32
Age, yr (m7SD) 40.9714.0 40.9713.5 47.3714.9
Sex, m; n (%) 13 (38%) 27 (53%) 13 (40%)
Smoking habit
Yes 4 (11%) 6 (11%) 4 (14%)
Ex 6 (18%) 16 (31%) 9 (27%)
No 24 (71%) 29 (58%) 19 (59%)
Atopy, yes, n (%) 21 (65%) 31 (58%) 16 (50%)
FEV1 (%pred) 100.1711.1 86.6714.7 59.0717.6
w
PD20FEV1 (g. mean) 0.494
z (n ¼ 21) 0.196 (n ¼ 28) 0.281 (n ¼ 4)
On IB/OB (n) 34 51 32
On OCS (n) 0 0 12
nPo0:05 compared with mild intermittent and mild persistent asthmatics.
wPo0:001 compared with mild persistent and moderate asthmatics.
zPo0:05 compared with moderate asthmatics.
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asthma severity was found as regards mean age,
sex, smoking habit and atopy distribution, in both
untreated and treated subjects. As expected, FEV1
and PD20FEV1 methacoline were significantly dif-
ferent among groups of asthma severity.
Tables 2 and 3 show absolute numbers and
percentages of sputum inflammatory cells and
ECP levels in sputum supernatant, in untreated
and treated subjects, respectively, compared with
the group of normal subjects.
The only severe asthmatic patient among the
untreated subjects was not considered in the
statistical analysis. All groups of untreated asth-
matics showed a higher cell count and percentage
of eosinophils, a higher percentage of neutrophils,
a lower percentage of macrophages, and a higher
concentration of ECP than normal subjects. Total
inflammatory cell number was not different among
groups of asthma severity as well as absolute
number and percentage of lymphocytes and neu-
trophils. The percentage of macrophages was
significantly lower in moderate asthmatic subjects.
Eosinophils were significantly higher in mild persis-
tent and moderate asthmatic subjects if compared
with mild intermittent asthmatic subjects, but no
difference was found between mild persistent and
moderate asthmatic subjects (Fig. 1). There was no
difference in ECP levels between the different
groups of asthma severity (Fig. 2).
All groups of treated asthmatics showed a higher
cell count and percentage of eosinophils, a higher
percentage of neutrophils, a lower percentage of
macrophages, and a higher concentration of ECP
than normal subjects. In treated subjects, total
inflammatory cells were higher in severe asth-
matics in comparison with other groups. Sputum
eosinophils (Fig. 1), ECP levels in the sputum
supernatant (Fig. 2) and sputum neutrophils in
absolute value but not in percentage, were
significantly higher in severe asthmatics in compar-
ison with mild persistent and moderate asthmatics.
These last two groups did not differ between them.
Macrophage percentage was lower in severe asth-
matics in comparison with the other two groups.
When severe asthmatics with unstable asthma,
despite high levels of antiasthma treatment, were
distinguished from stable severe asthmatics, no
difference in sputum eosinophils (16.2 (0.3–80.4)
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Table 2 Sputum characteristics of untreated subjects.
Controls Mild intermittent Mild persistent Moderate
Untreated subjects
Number 14 15 21 31
Infl. cells/ml ( 106) 0.5 (0.08–2.5) 0.47 0.52 0.54
(0.15–1.93) (0.15–2.5) (0.15–3.8)
Macro/ml ( 103) 372 (67–1789) 140 235 184
(6.7–540) (50–870) (21–875)
Neutro/ml ( 103) 144 (16–681) 135 300 300
(34–1400) (32–1700) (70–3500)
Eos/ml ( 103) 0 (0–2)n 4w 50 32
(0–241) (0–801) (0–1944)
Lymph/ml ( 103) 0.5 (0–19) 4 2 2
(0–45) (0–500) (0–20)
Inflamm. cells (%) 75.8 (42–94) 77.8 79 77.7
(31–99) (43–96) (31–97)
Macrophages (%) 69.5 (62–91)n 43.0 37.1 25.4z
(19.1–91.2) (11.3–70.8) (4.4–79.1)
Neutrophils (%) 25.2 (6–32)n 46.0 46.7 62.4
(7.1–78.3) (21.7–82.3) (12.3–94.7)
Eosinophils (%) 0.3 (0–0.8)n 1.3w 5.4 5.0
(0–12.9) (0–60.7) (0–80.1)
Lymphocytes (%) 1.9 (0–5.7) 0.7 0.5 0.1
(0–7.5) (0–2.3) (0–4)
ECP (ng/ml) 40 (10–122)n 63 (43–702) 154(13–1010) 360(11–1280)
(n ¼ 14) (n ¼ 6) (n ¼ 11) (n ¼ 21)
All data are expressed as median values with ranges.
nPo0:05 compared with mild intermittent, mild persistent and moderate asthmatics.
wPo0:05 compared with mild persistent and moderate asthmatics.
zPo0:05 compared with mild intermittent asthmatics.
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vs. 14.2 (0.1–78)%, N: 13 vs. 19) and ECP (1146 (66–
9316) vs. 1228 (0.7–9522) ng/ml, N: 6 vs. 13) was
observed.
Mild persistent and moderate asthmatic subjects
did not differ for any of the inflammatory markers
considered, both in untreated and treated subjects.
FEV1 (in % of the predicted value) correlated with
sputum eosinophils in absolute value in both
untreated and treated subjects, while correlated
also with eosinophils in percentage and with ECP in
treated subjects (Table 4). PD20FEV1 methacholine
showed a significant correlation with sputum
eosinophils and ECP levels only in untreated
subjects.
No difference was observed in sputum cells
between males and females. When sputum markers
were related to other clinical findings in all untreated
and treated subjects, a significant difference was
observed as regards age, subjects over 45yr showing
a higher total inflammatory cell counts (Po0:05) and
total neutrophil counts (Po0:05) in untreated sub-
jects, and a lower lymphocyte percentage in both
untreated and treated subjects (Po0:05), in compar-
ison with subjects under 45yr. Atopy was associated
with higher sputum eosinophil percentage in un-
treated (Po0:05) but not in treated subjects.
Current smokers showed higher ECP levels in un-
treated subjects (Po0:05), and higher total inflam-
matory and neutrophil counts (Po0:05) in treated
subjects, in comparison with ex-smokers and non-
smokers. When these differences in sputum markers
were examined in the different groups of asthma
severity, most of these differences were lost.
Discussion
In this study, we demonstrated that sputum eosino-
phils and sputum ECP levels were only partially able
to distinguish different degrees of asthma severity,
as defined according to the recommendations of the
International Guidelines, both in corticosteroid
untreated and treated subjects. In particular, mild
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Table 3 Sputum characteristics of treated subjects.
Controls Mild persistent Moderate Severe
Treated subjects
Number 14 34 51 32
Infl Cells/ml ( 103) 0.5 (0.08–2.5) 578 534 1041n
(90–2000) (72–8000) (195–14600)
Macro/ml ( 103) 372 (67–1789) 180 156 232
(19–930) (9–2537) (8–3900)
Neutro/ml ( 103) 144 (16–681) 272 302 507w
(10–1566) (29–4746) (70–10520)
Eos/ml ( 103) 0 (0–2)z 11 12 88w
(0–83) (0–1577) (2–2603)
Lymph/ml ( 103) 0.5 (0–19) 0 1 1
(0–19) (0–128) (0–87)
Inflamm. cells (%) 75.8 (42–94) 75.9 71.5 81z
(31.1–98.3) (35.4–97.6) (27–99)
Macrophages (%) 69.5 (62–91)z 41.7 35.7 18.8w
(3.3–93.3) (2–81.9) (3.4–50.0)
Neutrophils (%) 25.2 (6–32)z 54.6 59.6 54.7
(5.6–96.0) (16.7–96.6) (6.1–95.8)
Eosinophils (%) 0.3 (0–0.8)z 1.6 2.4 15.2w
(0.1–18.1) (0–45.4) (0.1–80.4)
Lymphocytes (%) 1.9 (0–5.7) 0.4 0.1 0.2
(0–2.4) (0–4.4) (0–1.7)
ECP (ng/ml) 40 (10–122)y 69.7(4–1000) 181(20–996) 1228(7–9500)w
(n ¼ 14) (n ¼ 20) (n ¼ 20) (n ¼ 19)
All data are expressed as median values with ranges.
nPo0:05 compared with mild persistent and moderate asthmatics.
wPo0:01 compared with mild persistent and moderate asthmatics.
zPo0:01 compared with mild persistent, moderate and severe asthmatics.
zpo0:05 compared with moderate asthmatics.
ypo0:01 compared with moderate and severe asthmatics.
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intermittent asthmatics and severe asthmatics were
both different from the other groups of asthma
severity, but mild persistent and moderate persis-
tent asthmatic subjects were similar as regards the
biological markers considered. Thus, clinical and
functional assessment of severity is not completely
reflected by the severity of eosinophilic airway
inflammation.
Eosinophils are considered as the main hallmark
of airway inflammation in asthma, and their
detection in sputum can be used to assess and
monitor the severity of airway inflammation.15
Because airway inflammation is believed to under-
line clinical and functional findings of asthma, it
should be possible to correlate markers of airway
inflammation (like sputum eosinophils or ECP) and
some clinical and functional parameters of asthma
severity. Several authors have correlated markers
of eosinophilic inflammation, measured in blood,
sputum, bronchoalveolar lavage or bronchial biop-
sies, with different clinical and functional find-
ings,6,16–18 showing, in general, a mild or poor
relationship. However, all these studies examined
single relationship with one clinical or functional
finding (like symptom score, FEV1, or PD20FEV1
methacholine), and not with an integrated evalua-
tion of symptoms, rescue medication use, PEF
variability and pulmonary function tests, as re-
commended by international guidelines.
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Figure 1 Box plots (median, interquartiles and 95th
percentiles) of sputum eosinophil percentages according
to asthma severity both in untreated and treated
subjects. (*) Po0:05; (**) Po0:01; (#) Po0:01 in
comparison with any group of asthmatic subjects.
Figure 2 Box plots (median, interquartiles and 95th
percentiles) of ECP levels (expressed as ng/ml) according
to asthma severity both in untreated and treated
subjects. (*) Po0:01; (y) Po0:05 compared with mild
intermittent asthmatics, Po0:01 compared with mild
persistent and moderate asthmatics. (#) Po0:01 com-
pared with moderate and severe asthmatics.
Table 4 Correlation between some functional
parameters and markers of eosinophilic inflamma-
tion.
FEV1% pred PD20FEV1%
Rho P Rho P
Untreated subjects
Eos/ml 0.26 0.03 0.49 0.005
Eos% 0.18 Ns 0.41 0.02
Log ECP 0.12 Ns 0.47 0.03
Treated subjects
Eos/ml 0.4 0.0001 0.16 Ns
Eos% 0.29 0.002 0.10 Ns
Log ECP 0.315 0.02 0.11 Ns
190 M.L. Bartoli et al.
Some studies have reported a significant differ-
ence in biological markers among groups of
subjects with asthma of different severity, as
assessed by Aas score9,16 or international guidelines
recommendations.10,11 While Aas score evaluates
the frequency of asthma symptoms and exacerba-
tions only, classification of asthma severity accord-
ing to international guidelines consider an
integrated evaluation of symptoms, use of rescue
medication, exacerbations and pulmonary func-
tion; furthermore, recently the minimum level of
antiasthma treatment able to control the disease
has been included in the evaluation of the severity
of asthma in subjects regularly treated.5 In two
studies which have used the classification of asthma
severity recommended by GINA, only mild incon-
sistent differences were detected among different
levels of asthma severity. However, some aspects
limit the relevance of the results obtained in these
studies. Firstly, subjects were not divided accord-
ing to the absence or presence of regular treatment
with inhaled or oral corticosteroids, and the
comparison between groups was strongly influ-
enced by the different antinflammatory asthma
treatment.10,11 Secondly, in one study mild persis-
tent and moderate asthmatic subjects were con-
sideded together in the same group, because the
possible masking effect of treatment on asthma
symptoms and pulmonary function.11 Finally, small
groups of asthmatic subjects were studied.
In the present study, we extended these evalua-
tions on a large sample of asthmatic subjects,
stratified according to corticosteroid treatment
and clinical and functional asthma severity assess-
ment as recommended by current international
guidelines. Sputum eosinophils differed greatly
between mild intermittent untreated subjects and
severe treated subjects, with both groups being
different from the other two groups (mild persis-
tent and moderate asthmatics). As expected,
untreated subjects with mild persistent or moder-
ate asthma showed higher sputum eosinophil
counts than the corresponding groups of treated
subjects. However, mild persistent and moderate
asthmatics were not different regarding sputum
eosinophilic markers, irrespective of the presence
of antiinflammatory treatment. Thus, while mild
intermittent and severe asthmatics seem to repre-
sent two different biological entities, at least
regarding eosinophilic inflammation, this cannot
be true for mild persistent and moderate asth-
matics. In this range of severity, as assessed by
clinical and functional findings, biological markers
can be different from one subject to another but
they do not distinguish these two levels of asthma
severity. Therefore, it is pertinent to discuss
whether there is really a clear-cut distinction
between mild persistent and moderate asthmatic
subjects. In effect, several pharmacologic studies
have considered a composite group of mild-to-
moderate asthmatics for the evaluation of the
efficacy of antiasthma treatment19,20 and single
subjects can spontaneously move from one to
another of these two steps of asthma severity in a
short period of time.
Severe asthmatics represent a particular and
heterogeneous group of asthmatic subjects. They
show a mix of eosinophilic and neutrophilic
inflammation, despite high level of antiasthma
treatment. In our study, severe asthmatics showed
high sputum eosinophil counts and ECP concentra-
tions, and high neutrophil counts, probably in
relationship with the increase of total inflammatory
cell counts. This is in agreement with previous
observations.16,21 In our study, no difference was
observed between stable and unstable severe
asthmatics, or between subjects with or without
oral corticosteroids. However, the heterogeneity of
this group of asthmatics has been well reported in
the literature22 and there are no data showing
biological differences among these subgroups of
severe asthmatics.
We used the classification of asthma severity
suggested by the most recent international guide-
lines5 which distinguish between untreated and
treated subjects. While in untreated subjects
assessment of frequency of symptoms and pulmon-
ary function is sufficient to define the level of
asthma severity, in treated subjects it is necessary
to take into account also the minimum level of
antiasthma treatment able to take asthma under
control. As an example, a subject with only
occasional symptoms and with normal FEV1, trea-
ted with the level of antiasthma treatment
recommended for moderate persistent asthma
(low to moderate doses of inhaled corticosteroids
plus regular bronchodilators) is believed to be
affected by moderate persistent asthma. Also, a
subjects with symptoms of mild persistent asthma
despite regular treatment with low dose inhaled
corticosteroids is believed to be affected by
moderate persistent asthma. Therefore, in treated
subjects the assessment of severity is more difficult
and it should require to have really optimized the
level of antiasthma treatment. In our study, among
subjects regularly treated attending to our asthma
clinic, we selected only subjects who were well
controlled with the minimum level of antiasthma
treatment, after a long period of surveillance.
The lack of a relationship between eosinophilic
inflammation and clinical and functional findings in
subjects with mild persistent to moderate asthma
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could have important consequences on asthma
management. In fact, in these patients, markers
of airway inflammation can add new informations
on the characteristics of the airway disease, and
they could have some practical importance in the
assessment of asthma control. Thus, presence of
eosinophilic inflammation could be a new method
to distinguish subtypes of asthmatic subjects in the
same category of asthma severity, and to target
treatment according to that. Previous data includ-
ing measurement of bronchial hyper-responsiveness
in the choice of the level of antiasthma treatment
have shown a better long-term outcome of asth-
ma.23 Recently, Green et al.24 demonstrated that in
moderate-to-severe asthmatic subjects a treat-
ment strategy aimed to normalization of sputum
eosinophils resulted in a greater reduction of acute
exacerbations and hospitalizations for asthma than
the usual strategy of control of symptoms and
pulmonary function.
Our study shows also that FEV1 was correlated
with sputum eosinophilic markers in treated sub-
jects, while PD20FEV1 methacholine did in un-
treated subjects only. This difference between
treated and untreated subjects can be explained
by a different range of FEV1 and PD20FEV1
methacholine in two groups.
Previous studies on this point have reported
conflicting results.6,25,26 When several confounding
factors were considered, sputum eosinophils corre-
lated with functional indices.27
In conclusion, we found that the assessment of
asthma severity according to clinical and functional
findings only partially corresponds to the severity of
eosinophilic airway inflammation as assessed by
induced sputum analysis. Mild intermittent and
severe asthmatics seem to represent two distinct
biological entities, while mild persistent and
moderate asthmatics do not differ between them
as regards eosinophilic airway inflammation. The
relevance of the measurement of airway inflamma-
tion in these groups of patients as regards asthma
management requires further investigation.
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